(Q34126534)

31 July 2017

title

Protection against persistence of hepatitis C. (English)

1 reference

31 July 2017

Stuart Ray

6

0 references

David Vlahov

series ordinal

8

object named as

David Vlahov

1 reference

31 July 2017

7

Steffanie A Strathdee

1 reference

31 July 2017

1

Shruti H Mehta

1 reference

31 July 2017

9

David L Thomas

1 reference

31 July 2017

Andrea Cox

2

1 reference

ORCID Public Data File 2021

Xiao-Hong Wang

series ordinal

4

object named as

Xiao-Hong Wang

1 reference

31 July 2017

Donald R Hoover

3

1 reference

31 July 2017

Qing Mao

series ordinal

5

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

31 July 2017

1 reference

31 July 2017

volume

359

1 reference

31 July 2017

issue

9316

1 reference

31 July 2017

page(s)

1478-1483

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Clinical outcomes after transfusion-associated hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Immunity in hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Two successive hepatitis C virus infections in an intravenous drug user

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniques.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Genetic epidemiology of hepatitis C virus throughout egypt

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Detection of specific sequences among DNA fragments separated by gel electrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

The natural history of hepatitis C virus infection: host, viral, and environmental factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2908435-0

7 January 2021

10.1016/S0140-6736(02)08435-0

Identifiers

DOI

1 reference

31 July 2017

1 reference